BreakSight®, Inc. harnesses a new technology that captures and maps sequence patterns of site-specific DNA breakage across a cell’s genome, revealing DNA-damaging mechanisms of specific drug targeting with high resolution. Our DDsite assay platform — paired with our DDinsight bioinformatics pipeline — enables pharmaceutical, biotech, and academic researchers to discover novel DNA biomarkers of drug response in the 98% of the genome that current biomarker platforms cannot reach. We offer drug screening characterization, mechanism-of-action studies, and biomarker discovery support for DDR inhibitor and genotoxic drug development programs via our DNA damage mapping and sequencing analysis platform.